Search Results - "Larrey, Dominique"

Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation by Meunier, Lucy, Larrey, Dominique

“…The hepatotoxicity of drugs is the main cause of drug withdrawal from the pharmaceutical market and interruption of the development of new molecules…”
Get full text

Chemotherapy-associated steatohepatitis by Meunier, Lucy, Larrey, Dominique

“…Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are…”
Get full text

EASL Clinical Practice Guidelines: Drug-induced liver injury by Andrade, Raúl J., Aithal, Guruprasad P., Björnsson, Einar S., Kaplowitz, Neil, Kullak-Ublick, Gerd A., Larrey, Dominique, Karlsen, Tom H.

“…Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs…”
Get full text

Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility by Meunier, Lucy, Larrey, Dominique

“…Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and the association with other autoimmune diseases is well-documented…”
Get full text

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) by Bourlière, Marc, Dr, Bronowicki, Jean-Pierre, MD, de Ledinghen, Victor, MD, Hézode, Christophe, MD, Zoulim, Fabien, MD, Mathurin, Philippe, MD, Tran, Albert, MD, Larrey, Dominique G, MD, Ratziu, Vlad, MD, Alric, Laurent, MD, Hyland, Robert H, DPhil, Jiang, Deyuan, PhD, Doehle, Brian, PhD, Pang, Phillip S, MD, Symonds, William T, PharmD, Subramanian, G Mani, MD, McHutchison, John G, MD, Marcellin, Patrick, MD, Habersetzer, François, MD, Guyader, Dominique, MD, Grangé, Jean-Didier, MD, Loustaud-Ratti, Véronique, MD, Serfaty, Lawrence, MD, Metivier, Sophie, MD, Leroy, Vincent, MD, Abergel, Armand, MD, Pol, Stanislas, MD

“…Summary Background Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of life-threatening complications, but…”
Get full text

Recent Advances in Hepatotoxicity of Non Steroidal Anti-inflammatory Drugs by Meunier, Lucy, Larrey, Dominique

“…AbstractNon-steroidal-anti-inflammatory drugs (NSAIDs) make a heterogenous pharmaco-therapeutic class of drugs among the most used drugs worldwide with various…”
Get full text

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis by Ratziu, Vlad, de Ledinghen, Victor, Oberti, Fréderic, Mathurin, Philippe, Wartelle-Bladou, Claire, Renou, Christophe, Sogni, Philippe, Maynard, Marianne, Larrey, Dominique, Serfaty, Lawrence, Bonnefont-Rousselot, Dominique, Bastard, Jean-Philippe, Rivière, Marc, Spénard, Jean

“…Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with increased morbidity and mortality. Ursodeoxycholic acid…”
Get full text

Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury by Delire, Bénédicte, De Martin, Eleonora, Meunier, Lucy, Larrey, Dominique, Horsmans, Yves

“…In the last 5 years, the landscape of oncologic treatment has been deeply modified with the development and use of immune checkpoint inhibitors (ICIs) that…”
Get full text

Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions by Burger, David, Back, David, Buggisch, Peter, Buti, Maria, Craxí, Antonio, Foster, Graham, Klinker, Hartwig, Larrey, Dominique, Nikitin, Igor, Pol, Stanislas, Puoti, Massimo, Romero-Gómez, Manuel, Wedemeyer, Heiner, Zeuzem, Stefan

“…Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other…”
Get full text

Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage by Cossais, Sabrina, Schwarzinger, Michaël, Pol, Stanislas, Fontaine, Hélène, Larrey, Dominique, Pageaux, Georges-Philippe, Canva, Valérie, Mathurin, Philippe, Yazdanpanah, Yazdan, Deuffic-Burban, Sylvie

“…This study evaluated the clinical and non-clinical determinants of health-related quality of life (HRQoL) associated with untreated chronic hepatitis C (CHC)…”
Get full text

Hepatitis C virus infection:are there still specific problems with genotype 3? by Gondeau, Claire, Pageaux, Georges Philippe, Larrey, Dominique

“…Hepatitis C virus(HCV) infection is one of the most common causes of chronic liver disease and the main indication for liver transplantation worldwide. As…”
Get full text

Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication by Faure, Stéphanie, Herrero, Astrid, Jung, Boris, Duny, Yohan, Daures, Jean-Pierre, Mura, Thibaut, Assenat, Eric, Bismuth, Michaël, Bouyabrine, Hassan, Donnadieu-Rigole, Hélène, Navarro, Francis, Jaber, Samir, Larrey, Dominique, Pageaux, Georges-Philippe

“…Background & Aims Beyond 5 years, poorer survival, related to alcohol relapse, is observed in patients with liver transplant for alcohol-related liver disease…”
Get full text

HLA associations with infliximab-induced liver injury by Bruno, Christopher D., Fremd, Brandon, Church, Rachel J., Daly, Ann K., Aithal, Guruprasad P., Björnsson, Einar S., Larrey, Dominique, Watkins, Paul B., Chow, Christina R.

“…Biomarkers that are able to identify patients at risk of drug-induced liver injury (DILI) after treatment with infliximab could be important in increasing the…”
Get full text

Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort) by Barré, Tangui, Nishimwe, Marie Libérée, Protopopescu, Camelia, Marcellin, Fabienne, Carrat, Fabrice, Dorival, Céline, Delarocque‐Astagneau, Elisabeth, Larrey, Dominique, Bourlière, Marc, Petrov‐Sanchez, Ventzislava, Simony, Mélanie, Pol, Stanislas, Fontaine, Hélène, Carrieri, Patrizia

“…Chronic hepatitis C virus (HCV) infection is a risk factor of insulin resistance, and HCV‐infected patients are at a high risk of developing diabetes. In the…”
Get full text

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France by Marcellin, Patrick, Zoulim, Fabien, Hézode, Christophe, Causse, Xavier, Roche, Bruno, Truchi, Régine, Pauwels, Arnaud, Ouzan, Denis, Dumortier, Jérôme, Pageaux, Georges-Philippe, Bourlière, Marc, Riachi, Ghassan, Zarski, Jean-Pierre, Cadranel, Jean-François, Tilliet, Valérie, Stern, Christiane, Pétour, Pascal, Libert, Olivier, Consoli, Silla M., Larrey, Dominique

“…Background and Aims Tenofovir disoproxil fumarate (TDF) demonstrated potent and sustainable antiviral efficacy and a good safety profile in patients with…”
Get full text

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141) by Deuffic-Burban, Sylvie, Schwarzinger, Michaël, Obach, Dorothée, Mallet, Vincent, Pol, Stanislas, Pageaux, Georges-Philippe, Canva, Valérie, Deltenre, Pierre, Roudot-Thoraval, Françoise, Larrey, Dominique, Dhumeaux, Daniel, Mathurin, Philippe, Yazdanpanah, Yazdan

“…Background & Aims In treatment-naive patients mono-infected with genotype 1 chronic HCV, treatments with telaprevir/boceprevir (TVR/BOC)-based triple therapy…”
Get full text

Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance? by Larrey, Dominique, Meunier, Lucy, Ursic-Bedoya, José

“…AbstractLiver biopsy is still useful in selected clinical situations in which it is the only tool to obtain information necessary for the diagnosis, the…”
Get full text

The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus by Molina, Sonia, Castet, Valérie, Fournier-Wirth, Chantal, Pichard-Garcia, Lydiane, Avner, Rachel, Harats, Dror, Roitelman, Joseph, Barbaras, Ronald, Graber, Pierre, Ghersa, Paola, Smolarsky, Moshe, Funaro, Ada, Malavasi, Fabio, Larrey, Dominique, Coste, Joliette, Fabre, Jean-Michel, Sa-Cunha, Antonio, Maurel, Patrick

“…Background/Aims The direct implication of low-density lipoprotein receptor (LDLR) in hepatitis C virus (HCV) infection of human hepatocyte has not been…”
Get full text

CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment by Meunier, Lucy, De Martin, Eleonora, Delire, Bénédicte, Jacot, Wiliam, Guiu, Severine, Zahhaf, Amel, Larrey, Dominique, Horsmans, Yves

“…Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the cornerstone of systemic therapy for patients with hormone receptor-positive, HER2-negative (HR+/HER2-)…”
Get full text

Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort by Hountondji, Lina, Ferreira De Matos, Christophe, Lebossé, Fanny, Quantin, Xavier, Lesage, Candice, Palassin, Pascale, Rivet, Valérian, Faure, Stéphanie, Pageaux, Georges-Philippe, Assenat, Éric, Alric, Laurent, Zahhaf, Amel, Larrey, Dominique, Witkowski Durand Viel, Philine, Riviere, Benjamin, Janick, Selves, Dalle, Stéphane, Maria, Alexandre Thibault Jacques, Comont, Thibaut, Meunier, Lucy

“…Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer therapy. Liver toxicity occurs in up to 25% of patients treated with ICIs. The aim of…”
Get full text